Abbott Laboratories Company Profile (NYSE:ABT)

About Abbott Laboratories (NYSE:ABT)

Abbott Laboratories logoAbbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States. Its Diagnostic Products include a range of diagnostic systems and tests. Its Nutritional Products include a range of pediatric and adult nutritional products. Its Company's Vascular Products include a range of coronary, endovascular, vessel closure and structural heart devices for the treatment of vascular disease. The Company, through St. Jude Medical, Inc., also offers products, such as rhythm management products, electrophysiology products, heart failure related products, vascular products, structural heart products and neuromodulation products.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Appliances & Equipment
  • Sub-Industry: Health Care Equipment
  • Symbol: NYSE:ABT
  • CUSIP: 00282410
  • Web: www.abbott.com
Capitalization:
  • Market Cap: $75.54 billion
  • Outstanding Shares: 1,735,272,000
Average Prices:
  • 50 Day Moving Avg: $43.74
  • 200 Day Moving Avg: $42.19
  • 52 Week Range: $36.76 - $45.84
P/E:
  • Trailing P/E Ratio: 45.30
  • Foreward P/E Ratio: 15.77
  • P/E Growth: 1.55
Sales & Book Value:
  • Annual Revenue: $22.3 billion
  • Price / Sales: 3.39
  • Book Value: $18.07 per share
  • Price / Book: 2.41
Dividend:
  • Annual Dividend: $1.06
  • Dividend Yield: 2.5%
Profitability:
  • EBIDTA: $4.77 billion
  • Net Margins: 6.71%
  • Return on Equity: 15.74%
  • Return on Assets: 8.27%
Debt:
  • Debt-to-Equity Ratio: 0.29%
  • Current Ratio: 1.56%
  • Quick Ratio: 1.25%
Misc:
  • Average Volume: 6.60 million shs.
  • Beta: 0.97
  • Short Ratio: 2.01
 

Frequently Asked Questions for Abbott Laboratories (NYSE:ABT)

What is Abbott Laboratories' stock symbol?

Abbott Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABT."

How often does Abbott Laboratories pay dividends? What is the dividend yield for Abbott Laboratories?

Abbott Laboratories declared a quarterly dividend on Friday, February 17th. Shareholders of record on Friday, April 14th will be given a dividend of $0.265 per share on Monday, May 15th. This represents a $1.06 annualized dividend and a yield of 2.44%. The ex-dividend date is Tuesday, April 11th. View Abbott Laboratories' Dividend History.

How were Abbott Laboratories' earnings last quarter?

Abbott Laboratories (NYSE:ABT) announced its earnings results on Wednesday, April, 19th. The company reported $0.48 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.43 by $0.05. The business had revenue of $6.34 billion for the quarter, compared to analyst estimates of $6.16 billion. Abbott Laboratories had a return on equity of 15.74% and a net margin of 6.71%. Abbott Laboratories's revenue for the quarter was up 29.7% on a year-over-year basis. During the same period last year, the firm posted $0.41 EPS. View Abbott Laboratories' Earnings History.

When will Abbott Laboratories make its next earnings announcement?

Abbott Laboratories is scheduled to release their next quarterly earnings announcement on Tuesday, July, 18th 2017. View Earnings Estimates for Abbott Laboratories.

What guidance has Abbott Laboratories issued on next quarter's earnings?

Abbott Laboratories updated its FY17 earnings guidance on Wednesday, April, 19th. The company provided earnings per share guidance of $2.40-2.50 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.45.

Where is Abbott Laboratories' stock going? Where will Abbott Laboratories' stock price be in 2017?

14 equities research analysts have issued twelve-month price objectives for Abbott Laboratories' stock. Their predictions range from $42.00 to $55.00. On average, they anticipate Abbott Laboratories' stock price to reach $48.64 in the next twelve months. View Analyst Ratings for Abbott Laboratories.

What are analysts saying about Abbott Laboratories stock?

Here are some recent quotes from research analysts about Abbott Laboratories stock:

  • 1. According to Zacks Investment Research, "Over the last three months, Abbott is trading below the broader Medical Products industry. While, sluggish pediatric business in China continues to hamper growth, we are also worried about the on-going economic problem in Venezuela that is expected to remain unresolved in the coming quarters. On a positive note, we are optimistic about its strong and consistent EPD and Medical Devices performance in the last reported first quarter. Overall, the company stands to benefit from the ongoing integration and synergy achievement of St. Jude. We are also looking forward to the company’s plans to focus on selling portfolio in core therapeutic areas. Very recently, Abbott also received CE mark for its TactiCath Sensor and Confirm Rx ICM products which is quite encouraging." (5/24/2017)
  • 2. Jefferies Group LLC analysts commented, "Investment summary: We are reiterating our Overweight rating for CORI and we are raising our PT by $2 to $12 following the positive donepezil patch bioequivalence results. Progress in the development of a proprietary pipeline is key, in our opinion, to the performance of the shares. Successful development of patch formulations of donepezil (Aricept) and/or memantine (Namenda) should position the company well to more-effectively monetize the transdermal drug delivery platform, in our opinion. Retention of meaningful commercialization rights could enable the company to turn the corner and pursue other opportunities more broadly, in our opinion. Corplex donepezil pilot study shows bioequivalence. Management reported that the Corplex donepezil pilot study met the FDA statistical criteria for bioequivalence. We note, too, that the patch was well-tolerated, with good skin and GI tolerability." (5/12/2017)

Who are some of Abbott Laboratories' key competitors?

Who owns Abbott Laboratories stock?

Abbott Laboratories' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (0.00%), BlackRock Inc. (0.00%), State Street Corp (4.64%), Massachusetts Financial Services Co. MA (0.00%), Wellington Management Group LLP (0.00%) and Bank of New York Mellon Corp (1.96%). Company insiders that own Abbott Laboratories stock include Brian B Yoor, Brian J Blaser, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jaime Contreras, Jared Watkin, Joseph J Manning, Michael J Warmuth, Miles D White, Robert B Ford, Robert E Funck, Roger Bird, Sally E Blount and Stephen R Fussell. View Institutional Ownership Trends for Abbott Laboratories.

Who sold Abbott Laboratories stock? Who is selling Abbott Laboratories stock?

Abbott Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Flossbach Von Storch AG, Pzena Investment Management LLC, FMR LLC, SG Americas Securities LLC, Macquarie Group Ltd., APG Asset Management N.V., Camber Capital Management LLC and Bahl & Gaynor Inc.. Company insiders that have sold Abbott Laboratories stock in the last year include Brian B Yoor, Daniel Gesua Sive Salvadori, Deepak S Nath, Heather L Mason, Hubert L Allen, Jared Watkin, Joseph J Manning, Michael J Warmuth, Robert E Funck, Roger Bird and Stephen R Fussell. View Insider Buying and Selling for Abbott Laboratories.

Who bought Abbott Laboratories stock? Who is buying Abbott Laboratories stock?

Abbott Laboratories' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Wellington Management Group LLP, Massachusetts Financial Services Co. MA, State Street Corp, Boston Partners, Geode Capital Management LLC and Bank of New York Mellon Corp. Company insiders that have bought Abbott Laboratories stock in the last two years include Brian J Blaser, Miles D White, Robert B Ford and Sally E Blount. View Insider Buying and Selling for Abbott Laboratories.

How do I buy Abbott Laboratories stock?

Shares of Abbott Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Abbott Laboratories stock cost?

One share of Abbott Laboratories stock can currently be purchased for approximately $43.53.

Analyst Ratings

Consensus Ratings for Abbott Laboratories (NYSE:ABT) (?)
Ratings Breakdown: 3 Hold Ratings, 11 Buy Ratings
Consensus Rating:Buy (Score: 2.79)
Consensus Price Target: $48.64 (11.73% upside)

Analysts' Ratings History for Abbott Laboratories (NYSE:ABT)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/16/2017Goldman Sachs Group IncInitiated CoverageNeutral -> Neutral$45.00LowView Rating Details
5/15/2017Royal Bank of CanadaReiterated RatingBuyLowView Rating Details
5/12/2017Jefferies Group LLCReiterated RatingBuy$50.00 -> $51.00LowView Rating Details
4/22/2017Cowen and CompanyReiterated RatingOutperform$48.00MediumView Rating Details
4/20/2017Barclays PLCBoost Price TargetOverweight -> Overweight$50.00 -> $52.00LowView Rating Details
4/19/2017Morgan StanleyReiterated RatingEqual Weight$42.00LowView Rating Details
4/18/2017Stifel NicolausReiterated RatingBuy$49.00MediumView Rating Details
3/14/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$48.00MediumView Rating Details
9/19/2016Bank of America CorpReiterated RatingBuyN/AView Rating Details
8/10/2016BTIG ResearchReiterated RatingBuy$45.00N/AView Rating Details
8/9/2016Deutsche Bank AGReiterated RatingBuyN/AView Rating Details
7/28/2016ArgusReiterated RatingBuy$55.00N/AView Rating Details
6/21/2016Edward JonesUpgradeHold -> BuyN/AView Rating Details
6/8/2016Credit Suisse Group AGReiterated RatingBuyN/AView Rating Details
5/12/2016Wells Fargo & CoReiterated RatingBuyN/AView Rating Details
4/30/2016S&P Equity ResearchReiterated RatingHoldN/AView Rating Details
4/30/2016GabelliReiterated RatingBuyN/AView Rating Details
4/28/2016Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
4/14/2016First GlobalDowngradeOutperform -> MarketperformN/AView Rating Details
3/28/2016Leerink SwannBoost Price TargetMarket Perform$37.00 -> $40.00N/AView Rating Details
1/29/2016Raymond James Financial, Inc.Lower Price TargetOutperform$46.00 -> $42.00N/AView Rating Details
1/29/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
5/27/2015Evercore Partners Inc.Initiated CoverageBuy$54.00N/AView Rating Details
5/26/2015Evercore ISIInitiated CoverageBuy$54.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Abbott Laboratories (NYSE:ABT)
Earnings by Quarter for Abbott Laboratories (NYSE:ABT)
Earnings History by Quarter for Abbott Laboratories (NYSE:ABT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/18/2017        
4/19/20173/31/2017$0.43$0.48$6.16 billion$6.34 billionViewN/AView Earnings Details
1/25/2017Q416$0.64$0.65$5.41 billion$5.33 billionViewListenView Earnings Details
10/19/2016Q316$0.58$0.59$5.29 billion$5.30 billionViewListenView Earnings Details
7/20/2016Q216$0.53$0.55$5.24 billion$5.30 billionViewListenView Earnings Details
4/20/2016Q116$0.39$0.41$4.77 billion$4.90 billionViewListenView Earnings Details
1/28/2016Q415$0.61$0.62$5.31 billion$5.20 billionViewListenView Earnings Details
10/21/2015Q315$0.53$0.54$5.16 billion$5.15 billionViewListenView Earnings Details
7/22/2015Q215$0.50$0.52$5.15 billion$5.20 billionViewListenView Earnings Details
4/22/2015Q115$0.42$0.47$4.85 billion$4.90 billionViewListenView Earnings Details
1/29/2015Q414$0.68$0.71$5.48 billion$5.36 billionViewListenView Earnings Details
10/22/2014Q314$0.60$0.62$5.62 billion$5.10 billionViewListenView Earnings Details
7/16/2014Q214$0.51$0.54$5.53 billion$5.55 billionViewListenView Earnings Details
4/16/2014Q114$0.36$0.41$5.29 billion$5.24 billionViewListenView Earnings Details
1/22/2014Q413$0.58$0.58$5.72 billion$5.66 billionViewListenView Earnings Details
10/16/2013Q313$0.52$0.55$5.46 billion$5.37 billionViewListenView Earnings Details
7/17/2013Q2 2013$0.44$0.46$5.53 billion$5.45 billionViewListenView Earnings Details
4/17/2013Q1 2013$0.41$0.42$5.42 billion$5.38 billionViewListenView Earnings Details
1/23/2013Q4 2012$1.50$1.51$10.58 billion$10.80 billionViewListenView Earnings Details
10/17/2012$1.28$1.30ViewN/AView Earnings Details
7/18/2012$1.22$1.23ViewN/AView Earnings Details
4/18/2012$1.00$1.03ViewN/AView Earnings Details
1/25/2012$1.44$1.45ViewN/AView Earnings Details
10/19/2011$1.17$1.18ViewN/AView Earnings Details
7/20/2011$1.12$1.12ViewN/AView Earnings Details
4/20/2011$0.90$0.91ViewN/AView Earnings Details
1/26/2011$1.29$1.30ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Abbott Laboratories (NYSE:ABT)
2017 EPS Consensus Estimate: $2.44
2018 EPS Consensus Estimate: $2.85
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.43$0.50$0.45
Q2 20172$0.60$0.61$0.61
Q3 20172$0.64$0.68$0.66
Q4 20172$0.72$0.73$0.73
Q1 20181$0.56$0.56$0.56
Q2 20181$0.71$0.71$0.71
Q3 20181$0.74$0.74$0.74
Q4 20181$0.84$0.84$0.84
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Abbott Laboratories (NYSE:ABT)
Most Recent Dividend:5/15/2017
Annual Dividend:$1.06
Dividend Yield:2.44%
Dividend Growth:22.90% (3 Year Average)
Payout Ratio:113.98% (Trailing 12 Months of Earnings)
42.91% (Based on This Year's Estimates)
38.41% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Dividend Payments by Quarter for Abbott Laboratories (NYSE:ABT)

Dividend History by Quarter for Abbott Laboratories (NYSE:ABT)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/17/2017quarterly$0.272.36%4/11/20174/14/20175/15/2017
12/9/2016quarterly$0.272.7%1/11/20171/13/20172/15/2017
9/15/2016quarterly$0.262.48%10/12/201610/14/201611/15/2016
6/10/2016quarterly$0.262.75%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.262.66%4/13/20164/15/20165/16/2016
12/11/2015quarterly$0.262.32%1/13/20161/15/20162/16/2016
9/17/2015quarterly$0.242.22%10/13/201510/15/201511/15/2015
6/12/2015quarterly$0.242%7/13/20157/15/20158/15/2015
2/20/2015quarterly$0.242.03%4/13/20154/15/20155/15/2015
12/12/2014quarterly$0.242.21%1/13/20151/15/20152/13/2015
9/11/2014quarterly$0.222.07%10/10/201410/15/201411/15/2014
6/13/2014quarterly$0.222.21%7/11/20147/15/20148/15/2014
2/21/2014quarterly$0.222.26%4/11/20144/15/20145/15/2014
10/16/2013quarterly$0.222.37%1/13/20141/15/20142/15/2014
9/12/2013quarterly$0.141.61%10/10/201310/15/201311/15/2013
6/14/2013quarterly$0.141.52%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.141.61%4/11/20134/15/20135/15/2013
12/14/2012quarterly$0.140.86%1/11/20131/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Abbott Laboratories (NYSE:ABT)
Insider Ownership Percentage: 0.26%
Institutional Ownership Percentage: 62.20%
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)
Insider Trades by Quarter for Abbott Laboratories (NYSE:ABT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/27/2017Roger BirdInsiderSell5,600$43.82$245,392.00View SEC Filing  
4/26/2017Joseph J ManningInsiderSell4,200$43.95$184,590.00View SEC Filing  
3/1/2017Michael J. WarmuthInsiderSell3,851$45.39$174,796.89View SEC Filing  
2/23/2017Robert E FunckVPSell25,500$45.50$1,160,250.00View SEC Filing  
2/22/2017Roger BirdInsiderSell13,222$45.02$595,254.44View SEC Filing  
2/21/2017Deepak S NathInsiderSell319$44.98$14,348.62View SEC Filing  
1/31/2017Heather L MasonInsiderSell35,700$40.77$1,455,489.00View SEC Filing  
12/20/2016Brian J BlaserInsiderBuy15,580$38.45$599,051.00View SEC Filing  
12/14/2016Robert B FordInsiderBuy12,775$39.09$499,374.75View SEC Filing  
11/10/2016Miles D WhiteChairmanBuy121,456$40.45$4,912,895.20View SEC Filing  
11/1/2016Sally E BlountDirectorBuy5,100$39.24$200,124.00View SEC Filing  
9/26/2016Daniel Gesua Sive SalvadoriSVPSell815$41.71$33,993.65View SEC Filing  
7/28/2016Stephen R FussellInsiderSell41,500$45.00$1,867,500.00View SEC Filing  
7/26/2016Michael J WarmuthInsiderSell26,800$43.49$1,165,532.00View SEC Filing  
7/25/2016Miles D WhiteChairmanBuy242,547$43.18$10,473,179.46View SEC Filing  
7/25/2016Robert E FunckVPSell26,800$43.08$1,154,544.00View SEC Filing  
6/28/2016Hubert L AllenEVPSell3,400$37.14$126,276.00View SEC Filing  
6/15/2016Jared WatkinSVPSell552$37.63$20,771.76View SEC Filing  
6/1/2016Brian B YoorCFOSell565$39.49$22,311.85View SEC Filing  
4/28/2016Deepak S NathSVPSell53$41.31$2,189.43View SEC Filing  
3/31/2016Jaime ContrerasSVPSell462$41.78$19,302.36View SEC Filing  
2/29/2016Brian B YoorCFOSell865$39.12$33,838.80View SEC Filing  
2/29/2016Deepak S NathSVPSell793$39.27$31,141.11View SEC Filing  
2/29/2016Robert B FordEVPSell1,706$39.28$67,011.68View SEC Filing  
2/29/2016Robert E FunckVPSell1,333$39.30$52,386.90View SEC Filing  
2/22/2016Jared WatkinSVPSell554$39.09$21,655.86View SEC Filing  
2/16/2016Deepak S. NathSVPSell171$37.13$6,349.23View SEC Filing  
12/16/2015Miles D. WhiteCEOSell438,000$46.00$20,148,000.00View SEC Filing  
8/18/2015Stephen R. FussellEVPSell13,096$50.46$660,824.16View SEC Filing  
4/27/2015Heather L MasonEVPSell13,500$47.45$640,575.00View SEC Filing  
4/27/2015Roger BirdSVPSell28,548$47.57$1,358,028.36View SEC Filing  
3/26/2015J. Scott WhiteSVPSell12,483$46.68$582,706.44View SEC Filing  
3/2/2015Jaime ContrerasSVPSell9,209$47.34$435,954.06View SEC Filing  
2/4/2015John M CapekEVPSell34,292$45.66$1,565,772.72View SEC Filing  
11/25/2014Jaime ContrerasSVPSell51,600$44.07$2,274,012.00View SEC Filing  
10/29/2014Miles D WhiteCEOSell440,800$42.52$18,742,816.00View SEC Filing  
3/3/2014John LandgrafEVPSell17,293$39.38$680,998.34View SEC Filing  
3/3/2014Katherine DoyleSVPSell6,639$39.01$258,987.39View SEC Filing  
3/3/2014Robert FunckVPSell1,413$38.97$55,064.61View SEC Filing  
2/18/2014John LandgrafEVPSell1,583$39.10$61,895.30View SEC Filing  
1/29/2014Michael WarmuthEVPSell11,430$36.21$413,880.30View SEC Filing  
12/6/2013Jean-Yves PaveeSVPSell5,855$37.46$219,328.30View SEC Filing  
11/7/2013Stephen FussellEVPSell10,466$37.59$393,416.94View SEC Filing  
10/30/2013Jaime ContrerasSVPSell25,368$36.85$934,810.80View SEC Filing  
6/7/2013Heather L MasonSVPSell12,000$37.01$444,120.00View SEC Filing  
2/1/2013William A OsbornDirectorBuy10,000$33.86$338,600.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Abbott Laboratories (NYSE:ABT)
Latest Headlines for Abbott Laboratories (NYSE:ABT)
Source:
DateHeadline
marketbeat.com logoFDA: Controller for heart pump recalled over deaths
marketbeat.com - May 24 at 6:29 PM
americanbankingnews.com logoAbbott Laboratories (ABT) Lowered to "Hold" at Zacks Investment Research
www.americanbankingnews.com - May 24 at 9:04 AM
finance.yahoo.com logoEdward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna
finance.yahoo.com - May 24 at 5:17 AM
nasdaq.com logoAbbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound? - Nasdaq
www.nasdaq.com - May 22 at 3:15 PM
finance.yahoo.com logoAbbott Labs (ABT) Down 2.3% Since Earnings Report: Can It Rebound?
finance.yahoo.com - May 22 at 3:15 PM
americanbankingnews.com logoAbbott Laboratories (ABT) Downgraded by TheStreet
www.americanbankingnews.com - May 21 at 10:34 PM
seekingalpha.com logoNew Div On The Block Quarterly Earnings Round-Up: Part 2
seekingalpha.com - May 21 at 1:19 AM
nasdaq.com logoVTV, ABT, MDLZ, AET: Large Outflows Detected at ETF
www.nasdaq.com - May 18 at 12:36 PM
americanbankingnews.com logoGoldman Sachs Group Inc Initiates Coverage on Abbott Laboratories (ABT)
www.americanbankingnews.com - May 16 at 8:56 PM
bizjournals.com logoFormer Angels, Orioles star convicted of insider trading
www.bizjournals.com - May 16 at 8:18 PM
thestreet.com logoGoldman Starts Abbott Laboratories at 'Neutral' - TheStreet.com
www.thestreet.com - May 16 at 3:17 PM
streetinsider.com logoGoldman Sachs Starts Abbott Labs (ABT) at Neutral - StreetInsider.com
www.streetinsider.com - May 16 at 3:17 PM
finance.yahoo.com logoGoldman Starts Abbott Laboratories at 'Neutral'
finance.yahoo.com - May 16 at 3:17 PM
americanbankingnews.com logoAbbott Laboratories (ABT) Lifted to Buy at Zacks Investment Research
www.americanbankingnews.com - May 16 at 10:57 AM
americanbankingnews.com logoAbbott Laboratories (ABT) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - May 15 at 9:42 AM
finance.yahoo.com logoRetired baseball player DeCinces found guilty of insider trading
finance.yahoo.com - May 12 at 8:30 PM
americanbankingnews.com logoAbbott Laboratories' (ABT) Buy Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - May 12 at 7:46 AM
nasdaq.com logoIYY, AGN, ABT, MDLZ: Large Outflows Detected at ETF
www.nasdaq.com - May 11 at 12:03 AM
finance.yahoo.com logoAbbott Announces CE Mark for TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™
finance.yahoo.com - May 9 at 9:31 AM
seekingalpha.com logoBuying A Very Safe Dividend
seekingalpha.com - May 8 at 8:17 PM
finance.yahoo.com logoAbbott Laboratories – Value Analysis (NYSE:ABT) : May 8, 2017
finance.yahoo.com - May 8 at 8:17 PM
finance.yahoo.com logoAbbott Announces National Reimbursement for FreeStyle® Libre in France, Providing Access to Revolutionary Technology for People with Diabetes
finance.yahoo.com - May 8 at 11:29 AM
finance.yahoo.com logoAbbott Announces CE Mark and First Use of the World's First Smartphone Compatible Insertable Cardiac Monitor
finance.yahoo.com - May 8 at 11:29 AM
americanbankingnews.com logo Analysts Expect Abbott Laboratories (ABT) Will Post Quarterly Sales of $6.63 Billion
www.americanbankingnews.com - May 7 at 7:54 AM
seekingalpha.com logoAbbott's Interesting Quarter - Seeking Alpha
seekingalpha.com - May 6 at 3:27 PM
americanbankingnews.com logoAbbott Laboratories (ABT) Expected to Post Earnings of $0.60 Per Share
www.americanbankingnews.com - May 5 at 8:24 PM
finance.yahoo.com logoAbbott Laboratories breached its 50 day moving average in a Bullish Manner : ABT-US : May 5, 2017
finance.yahoo.com - May 5 at 3:17 PM
seekingalpha.com logoAnalysis Of AbbVie's Pipeline: What's Left Of Abbott's Biopharma Growth Opportunities?
seekingalpha.com - May 4 at 3:16 PM
americanbankingnews.com logoAbbott Laboratories (ABT) Given Daily News Sentiment Score of 0.09
www.americanbankingnews.com - May 2 at 7:48 AM
finance.yahoo.com logoAlere, set to be acquired by Abbott, dealt setback in Medicare case
finance.yahoo.com - May 1 at 3:17 PM
americanbankingnews.com logoAbbott Laboratories (ABT) Given Daily Media Impact Rating of 0.18
www.americanbankingnews.com - April 29 at 8:42 AM
americanbankingnews.com logoJoseph J. Manning Sells 4,200 Shares of Abbott Laboratories (ABT) Stock
www.americanbankingnews.com - April 29 at 1:09 AM
americanbankingnews.com logoAbbott Laboratories (ABT) Insider Sells $245,392.00 in Stock
www.americanbankingnews.com - April 29 at 1:09 AM
seekingalpha.com logoAbbott launches nutrition drinks for surgery patients - Seeking Alpha
seekingalpha.com - April 26 at 3:25 PM
finance.yahoo.com logoAbbott Introduces Science-Based Nutrition Drinks to Help Patients Have a Better Recovery from Surgery
finance.yahoo.com - April 26 at 3:25 PM
americanbankingnews.com logoAbbott Laboratories (ABT) Getting Somewhat Negative Media Coverage, Analysis Shows
www.americanbankingnews.com - April 26 at 9:18 AM
finance.yahoo.com logoGlobal Market For Medical Implants To Hit Nearly $27 Billion In 5 Years
finance.yahoo.com - April 26 at 5:54 AM
seekingalpha.com logoAbbott's First Quarter: Medical Device Segment Grows Over 100%
seekingalpha.com - April 25 at 3:17 PM
finance.yahoo.com logoCramer's lightning round: Nobody ever made money betting against this CEO
finance.yahoo.com - April 25 at 6:37 AM
seekingalpha.com logoAbbott Laboratories: Constantly Adapting For Enduring Success
seekingalpha.com - April 24 at 11:18 AM
americanbankingnews.com logoQ3 2017 EPS Estimates for Abbott Laboratories Cut by Leerink Swann (ABT)
www.americanbankingnews.com - April 24 at 8:44 AM
americanbankingnews.com logoAbbott Laboratories (ABT) Receiving Somewhat Positive Media Coverage, Study Shows
www.americanbankingnews.com - April 23 at 7:32 AM
americanbankingnews.com logoCowen and Company Reiterates Outperform Rating for Abbott Laboratories (ABT)
www.americanbankingnews.com - April 22 at 7:14 AM
americanbankingnews.com logoLeerink Swann Comments on Abbott Laboratories' FY2021 Earnings (ABT)
www.americanbankingnews.com - April 21 at 6:02 PM
americanbankingnews.com logoFY2019 EPS Estimates for Abbott Laboratories (ABT) Increased by Analyst
www.americanbankingnews.com - April 21 at 5:37 PM
americanbankingnews.com logoWilliam Blair Weighs in on Abbott Laboratories' FY2017 Earnings (ABT)
www.americanbankingnews.com - April 21 at 2:30 PM
americanbankingnews.com logoAbbott Laboratories Target of Unusually Large Options Trading (ABT)
www.americanbankingnews.com - April 21 at 7:09 AM
nasdaq.com logoAbbott Laboratories (ABT) Tops Q1 Earnings & Sales Estimates - Nasdaq
www.nasdaq.com - April 21 at 1:39 AM
streetinsider.com logoCowen Reiterates Outperform Rating and $48 PT on Abbott Labs ... - StreetInsider.com
www.streetinsider.com - April 20 at 3:17 PM
streetinsider.com logoAbbott Labs (ABT) PT Raised to $52 at Barclays Following 1Q Report - StreetInsider.com
www.streetinsider.com - April 20 at 3:17 PM

Social

Chart

Abbott Laboratories (ABT) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff